臨床外科79巻2号

2024年02月発行

特集 ゲノム医学を外科診療に活かす！ 癌種別・ゲノム情報の治療選択への活用

膵癌

著者： 金井雅史¹

所属機関： ¹京都大学大学院医学研究科腫瘍薬物治療学講座

ページ範囲：P.197 - P.201

【ポイント】
◆KRAS野生型の膵癌患者では，4割近くにゲノムプロファイリングで治療標的となりうる遺伝子変異が見つかる．
◆リキッドバイオプシーではKRAS変異の検出割合が5割未満に下がるため，検査申し込みのタイミングに留意する必要がある．
◆ctDNAを用いた微小残存病変のモニタリングは，術後再発の早期診断や手術の適格患者の選別など，外科診療への応用が期待されている．

参考文献

1）国立がん研究センターがんゲノム情報管理センター：C-CAT登録状況〔https://for-patients.c-cat.ncc.go.jp/registration_status/〕（2023/10/07アクセス）

2）日本膵癌学会膵癌診療ガイドライン改訂委員会（編）：膵癌診療ガイドライン，2022年版．金原出版，2022

3）Akagi K, Oki E, Taniguchi H et al：Nationwide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers. J Clin Oncol 38（4-suppl）：803, 2020

4）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer：results from the phase II KEYNOTE-158 study. J Clin Oncol 38：1-10, 2020

5）Yoshino T, Pentheroudakis G, Mishima S, et al：JSCO-ESMO-ASCO-JSMO-TOS：international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31：861-872, 2020

6）Umemoto K, Yamamoto H, Oikawa R, et al：The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst 114：1279-1286, 2022

7）Golan T, Kanji ZS, Epelbaum R, et al：Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111：1132-1138, 2014

8）Reiss KA, Yu S, Judy R, et al：Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precis Oncol 2：1-9, 2018

9）Wattenberg MM, Asch D, Yu S, et al：Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 122：333-339, 2020

10）Golan T, Hammel P, Reni M, et al：Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381：317-327, 2019

11）Singhi AD, George B, Greenbowe JR, et al：Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156：2242-2253.e4, 2019

12）Sokol ES, Pavlick D, Khiabanian H, et al：Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol 4：442-465, 2020

13）Momozawa Y, Sasai R, Usui Y, et al：Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 8：871-878, 2022

14）Lee MS, Pant S：Personalizing medicine with germline and somatic sequencing in advanced pancreatic cancer：current treatments and novel opportunities. Am Soc Clin Oncol Educ Book 41：1-13, 2021

15）Strickler JH, Satake H, George TJ, et al：Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 388：33-43, 2023

16）Kondo T, Kanai M, Matsubara J, et al：Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer：prospective multicenter observational study. Med Oncol 40：144, 2023

17）Umemoto K, Sunakawa Y, Ueno M, et al：Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Br J Cancer 128：1603-1608, 2023

18）Sausen M, Phallen J, Adleff V, et al：Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6：7686, 2015

19）Groot VP, Mosier S, Javed AA, et al：Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res 25：4973-4984, 2019

20）Guo S, Shi X, Shen J, et al：Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Br J Cancer 122：857-867, 2020

21）Doebele RC, Drilon A, Paz-Ares L, et al：Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours：integrated analysis of three phase 1-2 trials. Lancet Oncol 21：271-282, 2020